

## Handling of patients with multi-resistant bacteria. How we do it in France ...

## Preventing emergent and highly resistant bacteria spread: 2013 French guidelines

Bruno GRANDBASTIEN

Medical School Henri Warembourg, University of Lille Infectiious Risk Management Department, University Hospital of Lille

High Council for Public Health, Patient Safety Committee

Haut Conseil de la Santé Publique

Prévention de la transmission croisée des Bactéries Hautement Résistantes aux antibiotiques émergentes (BHRe)

## Management of Multi-Drug Resistant (MDR) bacteria in France

- French Society for Hospital Hygiene (SF2H), 2009 & 2013: recommendations
  - Standard precautions
  - Additional "contact" precautions
  - [Additional "droplet" or "airborne" precautions]

• Public reporting



## Epidemiology of MDR bacteria in France: AP-HP Paris



Université de Lille 2 eror sawre 2 ero sawre 2 ero sawre

(ESBL) in acute care hospitals.

Fournier S. ARIC 2012

## Epidemiology of MDR bacteria in France: BMR-Raisin 2011





InVS - Raisin

## ... and for Extensively Drug-Resistant (XDR) bacteria management

- High Council for Public Health (HCSP), 2010
  - Vancomycin Resistant Enterococcus (VRE)
  - Carbapenemase Producing Enterobacteriaceae (CPE)





Conseil de la Santé

## Why new recommendations?

• Epidemiology contrasted for Vancomycin Resistant *Enterococcus (E. faecium)* - VRE in Europe





Conseil de la Santé

## **Epidemiology of VRE (E. faecium)** in Europe



2 DROIT ET SANTÉ

Publique

## Why new recommendations?

- Epidemiology contrasted for Vancomycin Resistant *Enterococcus (faecium)* - VRE in Europe
- Change of epidemiology for Carbapenemase Producing Enterobacteriaceae (CPE)





Conseil de la Santé

## **Epidemiology of carbapenem resistant** *K. pneumoniae* in Europe: %R



## Why new recommendations?

- Experiences in the management
  - of sporadic cases or grouped cases
  - in the context of a widespread epidemic
- Recommendations not always interpreted in the same manner
- Readability of the recommendations is affected by the multiplicity of documents (drafted as a response to formal requests by the HCSP, by type of microorganism or by type of situation), and by the multiplicity of regulatory texts.



. . .

## **Objectives**

<u>To update</u> and <u>standardise</u> all existing French recommendations concerning XDR bacteria

To make these recommendations more operational and comprehensible

To issue a common set of actions to be taken for VRE or CPE, and even for future emerging bacteria, which is transmissible through contact.



## **Definitions of XDR bacteria**

**ORIGINAL ARTICLE** 

International consensus
 (eCDC / CDC)

Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance

A.-P. Magiorakos<sup>1</sup>, A. Srinivasan<sup>2</sup>, R. B. Carey<sup>2</sup>, Y. Carmeli<sup>3</sup>, M. E. Falagas<sup>4,5</sup>, C. G. Giske<sup>6</sup>, S. Harbarth<sup>7</sup>, J. F. Hindler<sup>8</sup>, G. Kahlmeter<sup>9</sup>, B. Olsson-Liljequist<sup>10</sup>, D. L. Paterson<sup>11</sup>, L. B. Rice<sup>12</sup>, J. Stelling<sup>13</sup>, M. J. Struelens<sup>1</sup>, A. Vatopoulos<sup>14</sup>, J. T. Weber<sup>2</sup> and D. L. Monnet<sup>1</sup>

BACTERIOLOGY

- Three levels definitions:
  - MDR bacteria: non-susceptibility to at least one agent in three or more antimicrobial categories
  - XDR bacteria: non-susceptibility to at least one agent in all but two or fewer antimicrobial categories
  - PDR bacteria: non-susceptibility to all agents in all antimicrobial categories



## Definition of emerging Extensively Drug-Resistant bacteria (<u>e</u>XDR) in France

- commensal bacteria of the gastrointestinal tract
- resistant to a number of antibiotics
- with resistance mechanisms transferable between bacteria
- which have only spread in France to date in sporadic or limited epidemic form



## ... in 2015 ...

 Vancomycin Resistant Enterococcus (VRE) *Enterococcus faecium* vanA or vanB

 Carbapenemase Producing Enterobacteriaceae (CPE)





http://www.hcsp.fr/



#### Review

#### French recommendations for the prevention of 'emerging extensively drug-resistant bacteria' (eXDR) cross-transmission<sup>☆</sup>

D. Lepelletier<sup>a, b,\*</sup>, P. Berthelot<sup>c</sup>, J.-C. Lucet<sup>d</sup>, S. Fournier<sup>e</sup>, V. Jarlier<sup>f, e</sup>, B. Grandbastien<sup>g</sup> and the National Working Group<sup>†</sup>

<sup>a</sup> Unité de Gestion du risque Infectieux, Service de Bactériologie-Hygiène Hospitalière, CHU Nantes, Nantes, France <sup>b</sup> Université de Nantes, EA 3826, UFR Médecine, Nantes, France

- <sup>c</sup> Unité d'Hygiène Inter-Hospitalière, Service des Maladies Infectieuses et Laboratoire des Agents Infectieux et Hygiène, CHU St-Etienne, St Etienne, France
- <sup>d</sup> Unité Hospitalière de Lutte contre l'Infection Nosocomiale, GH Bichat Claude Bernard, AP-HP, Paris, France <sup>e</sup> CLIN central de l'AP-HP, Paris, France
- <sup>f</sup>Laboratoire de Bactériologie, Hôpital La Pitié-Salpêtrière, AP-HP, Paris, France

<sup>g</sup> Unité de Lutte contre les Infections Nosocomiales, Service du Risque Infectieux, des Vigilances et d'Infectiologie, CHRU Lille, Lille, France

## **Methods**

- Multidisciplinary working group
- Analysis of international recommendations and scientific literature
- Interview of
  - French National Reference Centres (CNR) concerned
  - eCDC
- recommendations formulated by expert agreement



## Main ideas

### Three levels for prevention

- Standard Precautions (SP): systematic application for all patients, regardless of their infectious status
- Additional "contact " precautions : if MDR bacteria or a contagious infectious disease
- Specific "XDR" precautions: if XDR bacteria or uncontrolled MDR epidemic situation





# Major principles of these recommendations (1)

- Prior organization
  - Organization of <u>discovery systems</u> for patients at high risk of being carriers of eXDR (history of hospitalisation abroad within the last 12 months, medical repatriation, history of being an eXDR carrier), ideally using the hospital information system.



# Major principles of these recommendations (2)

- Prior organization for laboratories
  - Organization in each medical biology laboratory:
    - have available specific agar in order to <u>search 3GC-R</u> <u>enterobacteria</u> and <u>VRE</u>,
    - be able to <u>suspect</u> the presence of an eXDR bacteria
  - Establishment of functional links with a competent laboratory (e.g. from that region) or with the French National Reference Centre (CNR) for resistance to antibiotics



# Major principles of these recommendations (3)

- Management of eXDR patients
  - Systematic alerts from the laboratory to the Infection Control Team (ICT) of any suspected eXDR,
  - Notifications in accordance with the regulatory procedure for NI reporting
  - Implementation of an epidemic management plan in every institution, in every region



# Major principles of these recommendations (4)

- Management of eXDR patients
  - Audit of standard precautions (excreta with material resources including bedpans and adapted bedpan washers ...)
  - Control of the patient environment
  - Control of antibiotic prescriptions (systematic recourse to an "antibiotic" referent)



# Major principles of these recommendations (5)

• Evaluation of the transmission risk by ICT adapted to patient situation, line of care, conditions of

this care, epidemiological situation ...

• Screening "contact" patients to find secondary cases ; concentric circles



## **Different situations ...**

## different fact sheets

Fact sheet 1. General measures to be applied when eXDR bacteria is identified, regardless of the situation









Conseil de la



















Santé







Conseil de la







Conseil de la



Long-term control of carbapenemase-producing Enterobacteriaceae at the scale of a large French multihospital institution: a nine-year experience, France, 2004 to 2012

### S Fournier (sandra.fournier@sap.aphp.fr)<sup>+</sup>, C Montell<sup>+</sup>, M Lepainteur<sup>+</sup>, C Richard<sup>+</sup>, C Brun-Buisson<sup>+</sup>, V Jarlier<sup>+</sup>, AP-HP Outbreaks Control Group<sup>+</sup> 1. Injection Control Team, Direction de la Politique Médicale, Assistance Publique-Höpitaux de Paris, Paris, France

- Interction Control team, Direction de la Politique Medicale, Assistance Polipaeva de Paris, Paris, Parice
   Höpital Riderra, Assistance Publique-Höpitaux de Paris, Le Kremilin-Bicètre, France
   UPEC Univ Paris 12, Höpital Henri Mondor, Assistance Publique-Höpitaux de Paris, Crétell, France
   Interction Control Team, Direction de la Politique Médicale, UPMC Univ Paris of, 24, 5454, Laboratoire de Bactériologie, Höpital Pitié-Salpétrière, Assistance Publique-Höpitaux de Paris, France
   The members of the AP-HP Outbreaks Control Group ner listed at the end of the article

#### Citation style for this article-

Litation style for tim a article: Formier S, Montell C, Lepainteur M, Richard C, Brun-Bulsson C, Jarlier Y, AP-HP Ourbreaks Control Group. Long-term control of carbapenemase-producing Enterobacteriacea at the scale of a large French multihospiral institution: a nine year experience, France, zooq to zotz. Euro Survelli. zor4;19(19):pil=zo802. Available online: http://www.eurosurvelliance.org/YUMArticles2paStaticIol=20802

Article submitted on 22 April 2013 / published on 15 May 2014

## **Effectiveness of these** measures

#### FIGURE

Number of carbapenemase-producing Enterobacteriaceae (CPE) events (n=140) and proportion of outbreaks among these events at Assistance Publique-Hôpitaux de Paris, France, 2004-2012



A CPE event was defined as one index case (respectively defined as infected or colonised with CPE), followed or not by secondary case(s).

## In summary ...

- Emerging infectious risk in France
- Recommendations:
  - risk assessment for each situation
  - Standard Precautions (PS)
     + Additional contact precautions (ACP)
     + specific eXDR precautions
  - screening
- Need to prior organization (anticipation)
- Responsiveness



## Acknowledgments

#### Composition of the working group

Astagneau Pascal	Public Health Physician	CCLIN Paris-Nord, Paris, CSSP	
Baud Olivier	Infection Control Practitioner	ARLIN Auvergne, Clermont-Ferrand	
Berthelot Philippe	Infection Control Practitioner	Saint Etienne UHC, CSSP, Chairman of SF2H, 2013 eXDR group co-pilot	
Blanckaert Karine	Infection Control Practitioner	ARLIN Nord, Lille	
Bonnet Richard	Microbiologist	Clermont-Ferrand UHC, CA-SFM, Associated National Reference Centre (CNR), SFM	
Bouscarra Joël	Rehabilitation Physician	Follow-up care and rehabilitation, Collioure	
Coignard Bruno	Medical Epidemiologist	InVS, Saint-Maurice, CSSP	
Ducron Corinne	Infection Control Head Nurse	Béthune HC	
Fournier Sandra	Infectious Diseases Specialist	AP-HP, Paris	
Grandbastien Bruno	Infection Control Practitioner	Lille UHC, Chairman of the CSSP, SF2H	
Jarlier Vincent	Microbiologist	AP-HP, Paris, CA-SFM	
Le Coustumier Alain	Microbiologist	Cahors HC, ColBVH	
Lepelletier Didier	Infection Control Practitioner	Nantes UHC, CSSP and SF2H, 2010 XDR and 2013 eXDR group co-pilot and reporter	
Lucet Jean-Christophe	Infection Control Practitioner	AP-HP, Paris, SF2H	
Mallaval Franck-Olivier	Infection Control Practitioner	Chambéry HC	
Nicolas-Chanoine Marie-Hélène	Microbiologist	AP-HP, Paris, Chairman of ONERBA, CA-SFM	
Rabaud Christian	Infectious Diseases Specialist	Nancy UHC, CSSP, CCLIN Est, Chairman of SPILF	
Souweine Bertrand	Intensive Care Specialist	Clermont-Ferrand, member of the ESBLE (Extended Spectrum Beta-Lactamase-Producing Enterobacteriaceae) Working Group, HCSP 2010	
van de Woestyne Philippe	Administrative Director	Lille UHC	
van der Mee-Marquet Nathalie	Microbiologist, Hygiene Specialist	Tours UHC, French Centre Network of Hygiene Specialists, ARLIN	
Vaux Sophie	Epidemiology Pharmacist	InVS, Saint-Maurice	

## **Acknowledgments**

Project managers					
Gagnaire Julie	University Hospital Assistant		Saint-Etienne UHC		
Lasserre Camille	University Hospital Assistant		Nantes UHC, currently Brest UHC		
Experts interviewed					
Anna-Pelagia Magiorakos	Infectious Diseases Specialist	Antimicrobial Resistance and Healthcare-Associated Infections, European Centre for Disease Prevention and Control, Stockholm, Sweden			
Roland Leclercq	Microbiologist	CNR Enterococci expert laboratory, Caen UHC			
Nicolas Fortineau	Microbiologist	Laboratory associated with the CNR Resistance to antibiotics, Bicêtre, AP-HP, Paris			
Group of lecturers					
Christian Brun-Buisson	Intensive Care Physician	Chairman of CoSPIN (DGOS) [Follow-up Committee of the Nosocomial Infections Prevention Programme (French General Directorate of Health Care Supply)], Créteil UHC, AP- HP, Paris			
Joseph Hajjar	Infection Control Practitioner	Valence HC			
Pierre Parneix	Infection Control Practitioner	Head of the CCLIN Sud-Ouest			
Thierry Lavigne	Infection Control Practitioner	Strasbourg UHC			
Yasmina Berrouane	Infection Control Practitioner	Nice UHC			